KB-1244

Durvalumab

12247

Background of Durvalumab

Durvalumab is a monoclonal antibody of human IgG with a high affinity/selectivity to inhibit PD-L1 binding to PD-1 and CD 80 (but not with PD-L2). Therefore risk related to adverse effects due to PD-L2 inhibition is minimized. An open-label, dose-escalation phase I/II study investigated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of durvalumab monotherapy in NSCLC and urothelial cancer.

Specifications

Catalog Number	KB-1244
Antibody Name	Durvalumab
Isotype	Human IgG1,kappa
FC Muations	L234F/L235E/P331S
Target	PDL1
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Keizer RJ, Huitema AD, Schellens JH, Beijnen JH: Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010 Aug;49(8):493-507.
Botticella A, Mezquita L, Le Pechoux C, Planchard D: Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619885530.